Several cohorts investigated the TDP-43 in biofluids were rather large and included various degenerative disease groups such as ALS and FTD, and the TDP-43 levels in CSF and plasma varied among the studies, which might be attributed to the difference in experimental methods, sample collections, and storage methods. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.